[HTML][HTML] Extracellular vesicles as biological indicators and potential sources of autologous therapeutics in osteoarthritis

X Zhang, JL Huebner, VB Kraus - International Journal of Molecular …, 2021 - mdpi.com
International Journal of Molecular Sciences, 2021mdpi.com
Along with cytokines, extracellular vesicles (EVs) released by immune cells in the joint
contribute to osteoarthritis (OA) pathogenesis. By high-resolution flow cytometry, we
characterized 18 surface markers and 4 proinflammatory cytokines carried by EVs of various
sizes in plasma and synovial fluid (SF) from individuals with knee OA, with a primary focus
on immune cells that play a major role in OA pathogenesis. By multiplex immunoassay, we
also measured concentrations of cytokines within (endo) and outside (exo) EVs. EVs …
Along with cytokines, extracellular vesicles (EVs) released by immune cells in the joint contribute to osteoarthritis (OA) pathogenesis. By high-resolution flow cytometry, we characterized 18 surface markers and 4 proinflammatory cytokines carried by EVs of various sizes in plasma and synovial fluid (SF) from individuals with knee OA, with a primary focus on immune cells that play a major role in OA pathogenesis. By multiplex immunoassay, we also measured concentrations of cytokines within (endo) and outside (exo) EVs. EVs carrying HLA-DR, -DP and -DQ were the most enriched subpopulations in SF relative to plasma (25–50-fold higher depending on size), suggesting a major contribution to the SF EV pool from infiltrating immune cells in OA joints. In contrast, the CD34+ medium and small EVs, reflecting hematopoietic stem cells, progenitor cells, and endothelial cells, were the most significantly enriched subpopulations in plasma relative to SF (7.3- and 7.7-fold higher). Ratios of EVs derived from neutrophils and lymphocytes were highly correlated between SF and plasma, indicating that plasma EVs could reflect OA severity and serve as systemic biomarkers of OA joint pathogenesis. Select subsets of plasma EVs might also provide next generation autologous biological products for intra-articular therapy of OA joints.
MDPI